Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-23
2009-10-13
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S494000, C548S495000, C544S111000, C544S143000, C544S358000, C514S415000, C514S235200, C514S252130
Reexamination Certificate
active
07601751
ABSTRACT:
There is provided a series of substituted acyl guanidines of Formula (I)or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and R8as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production ofAβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
REFERENCES:
patent: 0 940 139 (1999-09-01), None
patent: WO 92/14697 (1992-09-01), None
Hussain, I. et al., “Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase”,Mol. Cell. Neurosci, (1999) 14: 419-427.
Lin, X. et al., “Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein”, Proceedings of the National Academy of Sciences of the USA, (2000) 97: 1456-1460.
Jennings, L.D., et al., “Acylguanidines as inhibitors of BACE-1: Variation of pyrrole ring substituents extending into the S1 and S3 pockets”, Abstracts of Papers, 230thACS National Meeting, Washington, D.C., United States, Aug. 28-Sept. 1, 2005 (2005).
Luo, Y., et al., “Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation”,Nature Neuroscience(2001) 4: 231-232.
Roberds, S.L. et al.,“BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics”,Human Molecular Genetics(2001) 10: 1317-1324.
Seiffert, D.; et al., “Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors”,J. Biol. Chem. (2000) 275, 34086-34091.
Selkoe, D. J., “Alzheimer's Disease: Genes, Proteins, and Therapy”,Physiol. Rev. (2001) 81, 741-766.
Selkoe, D. J., “Biochemical Analyses of Alzheimer's Brain Lesions lead to the Identification of αβand its Precursor”,Ann. Rev. Cell Biol. (1994) 10: 374-403.
Sinha, S., et al., “Purification and cloning of amyloid precursor protein β-secretase from human brain”,Nature(London) (1999) 402: 537-540.
Solvibile, W.R., et al., “Thiophene acyl guanidines as BACE1 inhibitors”, Abstracts of Papers, 230th ACS National Meeting, Washington, D.C., United States, Aug. 28-Sep. 1, 2005 (2005).
Stock, J.R., et al., “Acylguanidines as small molecule BACE1 inhibitors: Initial exploration of S1 and S2′ pockets”, Abstracts of Papers, 230th ACS National Meeting, Washington, D.C., United States, Aug. 28-Sep. 1, 2005 (2005).
Sukhdeo, M.N., et al., “Acylguanidines as small molecule BACE1 inhibitors: Optimization of the S1′ region”, Abstracts of Papers, 230th ACS National Meeting, Washington, D.C., United States, Aug. 28-Sep. 1, 2005 (2005).
Thal, D. R., et al., “Two typs of Sporadic Cerebral Amyloid Angiopathy”,J. Neuropath. and Exper. Neurology(2002) 61: 282-293.
Vassar, R., et al., “β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE”,Science(1999) 286: 735-741.
Walsh, D. M., et al., “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo”,Nature(2002) 416, 535-539.
Wolfe, M. S., “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential”,J. Med. Chem. (2001) 44, 2039-2060.
Yan, R. et al., “Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity”,Nature(1999) 402: 533-537.
Zhou, P., et al., “Acylguanidines as small molecule BACE1 inhibitors: Exploration of the S1 pocket”, Abstracts of Papers, 230th ACS National Meeting, Washington, D.C., United States, Aug. 28-Sep. 1, 2005 (2005).
Dee Michael F.
Macor John E.
Shi Jianliang
Thompson, III Lorin A.
Zusi F. Christopher
Algieri Aldo A.
Bristol--Myers Squibb Company
Levis John F.
Shameem Golam M
LandOfFree
Indole acetic acid acyl guanidines as β-secretase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole acetic acid acyl guanidines as β-secretase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole acetic acid acyl guanidines as β-secretase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4086419